Grassley Planning to Investigate Orphan Designation’s Impact on High Drug Prices

Drug Industry Daily
A A
Sen. Chuck Grassley (R-Iowa) is planning to examine the FDA’s orphan drug programs to find out if companies are using the designation to justify higher prices for common drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily